Where Startup Funding Is Actually Going in August 2026 (And What It Means If You're Raising)

Two funding rounds closed within days of each other in late July and early August 2026, and neither company makes a consumer app, a chatbot wrapper, or anything resembling the generic "AI for X" pitch that dominated headlines over the past two years. One digitizes lab testing and imaging so people can catch disease earlier. The other solves a physical bottleneck in how data moves between AI chips. Together they tell you more about where investor money is actually going right now than any trend report.

The two rounds that show where the smart money is going

Function Health raised $450 million in non-dilutive growth financing from General Catalyst's Customer Value Fund, announced in early August 2026. It's the Austin-based company's second major raise in eight months, following a $298 million Series B, and brings its total funding past $800 million since launching in 2023. Function's platform gives members direct access to more than 160 lab biomarker tests plus MRI and CT imaging, aimed at catching conditions like cancer and cardiac disease before symptoms appear. The financing follows two acquisitions completed earlier in 2026 — Getlabs, a nationwide mobile blood-draw network, and SuppCo, a supplement-tracking platform — that extended Function's infrastructure rather than just its user base.

Eliyan closed a $145 million Series C at a $1 billion valuation, announced July 29, 2026, officially making it a unicorn. The Santa Clara startup doesn't build AI models — it builds the interconnect technology that moves data between AI chips inside data centers, addressing a bottleneck where expensive GPUs sit underutilized because they can process data faster than current systems can feed it to them. The round was led by Seligman Ventures, with new strategic backing from Cisco Investments and Lumentum — corporate investors, not just financial ones, signaling that major hardware players see Eliyan's technology as infrastructure they'll actually need.

The pattern investors are betting on

Neither company is chasing the AI hype cycle in the way most 2024-era startups did. Function Health isn't an AI company at its core — it's a health infrastructure company that uses AI to interpret data it already owns exclusively (its own lab results, its own imaging). Eliyan isn't building on top of the AI boom — it's solving a physical constraint the AI boom itself created. Both are hard to copy quickly: Function through owned infrastructure (labs, imaging locations, acquired networks) and regulatory/clinical trust; Eliyan through deep semiconductor engineering expertise that isn't something a competitor can replicate with a few months of development.

That's a meaningfully different bet than funding a thin AI wrapper around someone else's model. It suggests investors in mid-2026 are pricing in the assumption that foundational-model access is no longer a moat — so they're paying up for companies whose advantage sits somewhere a competitor can't simply copy by calling the same API.

What this means if you're raising right now

If you're a founder preparing to raise, both rounds point at the same underlying question investors are asking earlier in the process than they used to: what do you own that a well-funded competitor can't replicate in six months? For Function, that's proprietary health data and physical infrastructure. For Eliyan, it's specialized engineering IP. Neither is "we built a product using GPT-5" — that's table stakes now, not a differentiator.

Practically, that means:

• Lead with what's structurally hard to copy, not with which AI model you're using. Investors have seen enough thin AI wrappers to discount that pitch specifically.
• Owned infrastructure and proprietary data are being treated as real moats again — a shift from the pure software-margin thinking that dominated the previous decade of startup investing.
• Corporate strategic investors, not just VCs, are showing up in rounds for companies solving problems those corporations will need solved themselves (Cisco and Lumentum in Eliyan's round is a clear example) — worth considering if your technology has an obvious industrial buyer or partner.

For a broader walkthrough of how startup funding works and how to prepare a raise from the ground up, see PrimeWorldMedia's guide on how to get startup funding in 2026.

Frequently Asked Questions

Is AI funding slowing down in 2026? No — but it's concentrating differently. Investors are still writing large checks into AI-adjacent companies, but increasingly toward businesses with proprietary data, technical depth, or infrastructure that's hard to replicate, rather than toward generic applications built on top of widely available models.

What is "non-dilutive" financing, like Function Health's round? Financing that doesn't require the company to give up equity in exchange for capital — often structured around revenue or customer-growth metrics instead. General Catalyst's Customer Value Fund, which led Function's round, specializes in this structure.

Why did corporate investors like Cisco and Lumentum join Eliyan's round instead of just VCs? Strategic corporate investors typically join a round when a startup's technology solves a problem the investing company will need solved for its own business — in this case, chip and networking infrastructure for AI data centers. Their participation is often read as a signal of real technical validation, not just financial confidence.

Does this mean smaller, earlier-stage startups can't raise right now? No. Early-stage deals are still happening — reporting on August 2026 funding activity has also highlighted smaller pre-seed and seed rounds for teams with strong technical founders, even without the scale of Function's or Eliyan's later-stage rounds. The pattern described here is most visible at growth and late stages, where investors are deploying the largest checks.